Rhone-Poulenc Rorer Inc. announced that its licensed patent forblood-clotting protein Factor VIII-C used to treat hemophiliahas been upheld by the European Patent Office despiteopposition from five European companies. The Factor VIII-Cpatent is owned by the Scripps Research Institute and Rhone-Poulenc has an exclusive license.

(c) 1997 American Health Consultants. All rights reserved.